Glaukos' iDose TR: A Game Changer in Glaucoma Treatment

Glaukos Corporation (NYSE: GKOS) recently announced positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, which includes the iDose TR (travoprost intracameral implant) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The iDose TR platform has shown promising results in two Phase 3 pivotal trials, demonstrating sustained substantial reductions in IOP and a favorable safety profile through 36 months.

In the 36-month follow-up analysis of the Phase 3 trials, approximately 70% of iDose TR subjects remained well-controlled on the same or fewer topical IOP-lowering medications at 36 months compared to screening, versus 58% of timolol control subjects. Additionally, 81% of iDose TR subjects were completely free of IOP-lowering topical medications at 12 months across both trials. The iDose TR platform also demonstrated excellent tolerability with 98% of iDose TR subjects continuing in the trial at 12 months, versus 95% of timolol control subjects across both Phase 3 trials.

The iDose TR platform's ability to provide sustained, long-duration efficacy with minimal side effects addresses the ubiquitous patient non-adherence and chronic side effects associated with topical medications. The platform is designed to deliver therapeutic levels of medication from within the eye for extended periods, reducing the need for daily eye drop treatment. Glaukos plans to move forward with its plans for an NDA submission to the U.S. FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.

The positive clinical updates for iDose TR leave Glaukos ideally positioned to advance its mission to transform vision therapies for the benefit of patients around the globe suffering from chronic eye diseases. The company continues to believe there is an important unmet clinical need and strong appetite within the ophthalmic community for safe, effective, and sustained procedural pharmaceutical alternatives to traditional topical medications. With the iDose TR platform, Glaukos is poised to revolutionize the treatment paradigm for patients with glaucoma or ocular hypertension, offering a more convenient, long-duration, and robust efficacy with minimal side effects.